Myriad Genetics will release its third quarter 2026 financial results on November 4, 2026, after market close. The molecular diagnostic testing company has scheduled a conference call for the same day at 4:30 pm ET to discuss its quarterly performance.

Earnings Call Details

Management will provide a financial overview and business update during the scheduled call. Investors can access a live webcast via the company’s Investor Relations website. For telephone participation, registrants must sign up in advance to receive a dial-in number and unique PIN. An archived version of the webcast will be available following the event.

Company Profile

Myriad Genetics operates as a leader in precision medicine, developing molecular tests that assist patients and providers in uncovering genetic insights. These tests evaluate disease risk and progression across various medical specialties, aiming to improve patient care through earlier detection and precise treatment decisions.

Myriad Genetics Inc. (NASDAQ: MYGN) promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026. The appointment marks a leadership transition within the molecular diagnostics firm’s commercial organization.

Sikri previously served as Senior Vice President of Product at Myriad for the past year. He brings extensive experience in molecular diagnostics and oncology to the new role. The company highlighted his track record in driving growth and operational excellence as key factors for the promotion.

Leadership Transition

Brian Donnelly, who served as Chief Commercial Officer since May 2025, will depart Myriad on September 21, 2026. Sam Raha, President and CEO of Myriad Genetics, thanked Donnelly for his contributions to the company.

Raha stated that Sikri’s domain knowledge will be instrumental in executing the company’s cancer care continuum focus and profitable growth strategy. Sikri expressed enthusiasm about leading the commercial organization and partnering with the executive team to advance Myriad’s mission.

Financial Outlook

Myriad reaffirmed its financial guidance for full-year 2026. This guidance was originally announced during the second quarter 2026 earnings call on July 30, 2026. The company did not provide updated specific figures in this announcement.